Clinical trials: Intravenous Injections
Waldenstrom's Macroglobulinemia, Non-Hodgkin's Lymphoma
Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies
The purpose of this study is to test the safety and tolerability of carfilzomib at different dose levels on hematological cancers such as multiple myeloma, non-Hodgkin's lymphoma, Hodgkin's disease, or Waldenstrom's…
- Conditions
- Waldenstrom's Macroglobulinemia, Non-Hodgkin's Lymphoma, Hodgkin's Disease, Multiple Myeloma
- Trial name
- NCT00150462
- Testing
- Carfilzomib, Dexamethasone
- Where
- 5 sites in United States
- Volunteers
- 48 people
- Sponsor
- Amgen
Healthy
A Study of IBI311 in Healthy Volunteers
It is designed for Multi-center, double-masked, randomized, placebo- control study with dose escalation phase I trial to evaluate the safety, tolerability, PK and immunogenicity profiles of a single intravenous injection of…
- Trial name
- NCT05480579
- Testing
- IBI311
- Where
- China
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Crigler-Najjar Syndrome Type I
Gene Therapy for Crigler Najjar Syndrome Type I (AlphaCN)
This is a Phase 1/2, multinational, open-label, study to evaluate the safety and efficacy of an intravenous infusion of GT-UGT1A1-AAV8-02 in patients with Crigler-Najjar type 1 aged ≤10 years and requiring phototherapy.
- Trial name
- NCT06641154
- Testing
- GT-UGT1A1-AAV8-02
- Where
- 2 sites in Russia
- Volunteers
- 5 people
- Sponsor
- Federal State Budget Institution Research Center for Obstetrics, Gynecology and Perinatology Ministry of Healthcare
Kidney Transplantation
Safety and Tolerance of Increased Doses of SHR-2106 Injection in Healthy Subjects
This is a randomized, double-blind, placebo-controlled phase I clinical study with the primary objective of evaluating the safety and tolerability of SHR-2106 in healthy subjects after a single intravenous or subcutaneous…
- Trial name
- NCT05948059
- Where
- China
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Advanced Solid Tumors
Phase I Study of Intravenous Lipotecan® (TLC388 HCl for Injection) in Patients With Advanced Solid Tumors
The purpose of this study is to find a safe and tolerable dose of Lipotecan® when administered to patients with advanced solid tumors.
- Trial name
- NCT00747474
- Testing
- Lipotecan
- Where
- 4 sites in United States, Taiwan
- Volunteers
- 54 people
- Sponsor
- Taiwan Liposome Company
Migraine Disorders, Headache
The Effect of Intravenous Fluid Therapy in Acute Migraine Attacks
The study is a single-center, double-blind, randomized protocol comparison. The study will be conducted in Marmara University School of Medicine Pendik Training and Research Hospital, Department of Emergency Medicine between…
- Conditions
- Migraine Disorders, Headache, Acute Pain
- Trial name
- NCT04287140
- Testing
- Bolus fluid administration
- Where
- Turkey (Türkiye)
- Volunteers
- 120 people
- Sponsor
- Marmara University
Ovarian Hyperstimulation Syndrome
Calcium for Prevention of Ovarian Hyperstimulation Syndrome
There are many protocols for prevention of ovarian hyperstimulation syndrome, intravenous calcium is a novel protocol. But still there is lack of evidence of it is real effect in prevention of OHSS \& the mechanism of its action…
- Trial name
- OHSS (NCT01427335)
- Testing
- calcium, 0.9 % saline
- Where
- Egypt
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Cairo University
Moderate-to-severe Inflammatory Bowel Disease
A Study to Evaluate the Safety of SHR-7590 in Chinese Healthy Participants and in Patients With Moderate-to-severe Inflammatory Bowel Disease
This Phase I first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SHR-7590 via subcutaneous or intravenous administration in Chinese healthy participants and patients with…
- Trial name
- NCT07758101
- Testing
- SHR-7590
- Where
- China
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
HIV Prevention, HCV
Integrated HIV Prevention and HCV Care for PWID
The objective of this study is to compare and evaluate two strategies of delivering PrEP and Hepatitis C Virus (HCV) treatment to people who inject drugs to determine the best method of providing care.
- Conditions
- HIV Prevention, HCV, Opioid Use, Intravenous Drug Usage
- Trial name
- M2HepPrEP (NCT03981445)
- Testing
- ARTAS Adapted Patient Navigation, Adherence Counseling
- Where
- 3 sites in United States, Canada
- Volunteers
- 446 people, healthy volunteers welcome
- Sponsor
- Columbia University
Injection Site Irritation, Pain
Lidocaine, Esmolol, or Placebo to Relieve IV Propofol Pain
The primary hypothesis is that esmolol and lidocaine, when given without the use of a tourniquet, provide relief of propofol injection pain that is superior to placebo when assessed using the propofol pain scoring tool
- Trial name
- NCT04356352
- Testing
- Lidocaine, Esmolol
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Wake Forest University Health Sciences
Carotid Stenosis
Gadobutrol Enhanced MRA of the Supra-aortic Vessels
Subjects referred for a routine CTA (computed tomography angiography) or MRA (magnetic resonance angiography) will be invited to participate in the study and subjects will be involved in the study for between 2 and 12 days.
- Trial name
- GEMSAV (NCT01344447)
- Testing
- Gadobutrol (Gadovist, BAY86-4875)
- Where
- 56 sites in United States, Argentina and 12 more
- Volunteers
- 479 people
- Sponsor
- Bayer
Healthy
A Study to Test How Well Healthy Men Tolerate BI 765250 When Given as an Infusion Into the Vein or as an Injection Under the Skin
The main objectives of this trial are to investigate safety, tolerability, pharmacokinetics and pharmacodynamics following single rising doses of BI 765250.
- Trial name
- NCT05151653
- Testing
- BI 765250
- Where
- Belgium
- Volunteers
- 139 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Hepatic Insufficiency
Phase 1 Hepatic Insufficiency Trial of Methoxyethyl Etomidate Hydrochloride
A Phase I clinical study to compare the pharmacokinetics, pharmacokinetics, and safety of intravenous administration of methoxyetomidate hydrochloride for injection in subjects with mild hepatic insufficiency (Child-pugh A)…
- Trial name
- NCT06176716
- Testing
- ET-26
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Ahon Pharmaceutical Co., Ltd.
Pneumonia, Pneumocystis Carinii, HIV Infections
A Treatment Protocol for the Use of Trimetrexate With Leucovorin Rescue for AIDS Patients With Pneumocystis Carinii Pneumonia and Serious Intolerance to Approved Therapies
To determine the safety and effectiveness of an investigational drug trimetrexate (TMTX) with leucovorin rescue (LCV) in the treatment of Pneumocystis carinii pneumonia (PCP) in patients who have AIDS, are HIV positive, or are at…
- Trial name
- NCT00001016
- Testing
- Trimetrexate glucuronate, Leucovorin calcium
- Where
- United States
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Alzheimer's Disease
SLS-005 (Trehalose Injection) in the Treatment of Alzheimer's Disease
An open-label, proof-of-concept study to evaluate the safety and treatment effects of SLS-005 in Participants with Alzheimer's Disease (AD) treated once or twice weekly for 52 weeks.
- Trial name
- [STRIVE-AD] (NCT05332678)
- Testing
- SLS-005 - Once Weekly, SLS-005 - Twice Weekly
- Where
- 3 sites in Australia
- Sponsor
- Seelos Therapeutics, Inc.
Breast Cancer
Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast Magnetic Resonance Imaging (MRI)
The purpose of this study is to look at the efficacy (how does it work) and safety of gadobutrol when used for obtaining MR images of both breasts.Women with a recent diagnosis of breast cancer by mammogram (X-ray examination of…
- Trial name
- GEMMA 2 (NCT01104584)
- Testing
- Gadobutrol (Gadavist, Gadovist, BAY86-4875)
- Where
- 48 sites in United States, Argentina and 7 more
- Volunteers
- 460 people
- Sponsor
- Bayer
Pneumonia, Myocardial Injury
Study of Intravenous TAD® 600 Mg/4 ML Solution for Injection to Evaluate Efficacy and Safety in Preventing Myocardial Injury in Patients with Pneumonia.
The goal of this PHASE III clinical trial is to evaluate efficacy and safety of intravenous TAD® 600 mg/4 mL solution for injection in preventing myocardial injury in patients with pneumonia.
- Trial name
- NCT06296212
- Testing
- TAD® 600 mg/4 mL powder and solvent for solution for injection, Saline solution 0.9% of sodium chloride
- Where
- 7 sites in Italy
- Volunteers
- 178 people
- Sponsor
- Biomedica Foscama S.p.A. Industria Chimico-Farmaceutica
Injections, Intravenous, Administration, Intravenous
A Trial to Demonstrate the Safety and Efficacy of the OptiVein IV Catheter In a Pediatric Population
A prospective, single-center, open-label, randomized controlled trial to demonstrate the safety and efficacy of the OptiVein IV Catheter in the pediatric population.
- Trial name
- NCT03145519
- Testing
- Vasofix Certo Catheter, OptiVein Catheter
- Where
- Estonia
- Volunteers
- 188 people
- Sponsor
- Optomeditech Oy
Arthritis, Rheumatoid
Evaluating Safety of Escalating Doses of Tilmanocept by IV Injection and SPECT Imaging in Subjects With and Without RA
Prospective, open-label, multicenter, dose escalation, safety with pharmacokinetics (PK) and dosimetry study of injected Tc 99m tilmanocept in the detection of and assessment of localization to skeletal joints in subjects with…
- Trial name
- NCT02865434
- Testing
- Tc99m-tilmanocept, SPECT Imaging (60 Minutes post-injection), SPECT Imaging (180 Minutes post-injection)
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Navidea Biopharmaceuticals
Metastatic Cancer, Cancer
A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer
The goal of this Phase 1 clinical research study is to find the highest safe dose of BIND-014 that can be given in the treatment of patients with advanced or metastatic cancer.
- Conditions
- Metastatic Cancer, Cancer, Solid Tumors
- Trial name
- NCT01300533
- Testing
- BIND-014
- Where
- 6 sites in United States
- Volunteers
- 58 people
- Sponsor
- BIND Therapeutics